Aadi Bioscience, Inc. (AADI)
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
$44.20M
Mr. Brendan P. Delaney M.B.A.
76.00
Pacific Palisades, CA
Aug 08, 2017
-0.71
$-2.55
2.71
5.16
-288.72%
-0.68
-0.02
0.52
1.79
4.69
-61.97%
-61.83%
Similar stocks (14)
Revolution Medicines, Inc.
RVMD
Crinetics Pharmaceuticals, Inc.
CRNX
Ultragenyx Pharmaceutical Inc.
RARE
Arvinas, Inc.
ARVN
Kura Oncology, Inc.
KURA
Erasca, Inc.
ERAS
AnaptysBio, Inc.
ANAB
Aerovate Therapeutics, Inc.
AVTE
Monte Rosa Therapeutics, Inc.
GLUE
Acrivon Therapeutics, Inc. Common Stock
ACRV
Design Therapeutics, Inc.
DSGN
Rezolute, Inc.
RZLT
AN2 Therapeutics, Inc.
ANTX
Anebulo Pharmaceuticals, Inc.
ANEB
ETF Exposure (17)
iShares Micro-Cap ETF
IWC
0.00679%
iShares Russell 2000 Value ETF
IWN
0.00207%
iShares Russell 2000 ETF
IWM
0.00109%
ProShares Ultra Russell2000
UWM
3.77731127157404e-4%
ProShares Hedge Replication ETF
HDG
1.9421563799476015e-4%
ProShares UltraPro Russell2000
URTY
1.7282742178948004e-4%
Global X Russell 2000 Covered Call ETF
RYLD
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Revolution Medicines, Inc.
RVMD
Crinetics Pharmaceuticals, Inc.
CRNX
Ultragenyx Pharmaceutical Inc.
RARE
Arvinas, Inc.
ARVN
Kura Oncology, Inc.
KURA
Erasca, Inc.
ERAS
AnaptysBio, Inc.
ANAB
Aerovate Therapeutics, Inc.
AVTE
Monte Rosa Therapeutics, Inc.
GLUE
Acrivon Therapeutics, Inc. Common Stock
ACRV
Design Therapeutics, Inc.
DSGN
Rezolute, Inc.
RZLT
AN2 Therapeutics, Inc.
ANTX
Anebulo Pharmaceuticals, Inc.
ANEB
ETF Exposure (17)
iShares Micro-Cap ETF
IWC
0.00679%
iShares Russell 2000 Value ETF
IWN
0.00207%
iShares Russell 2000 ETF
IWM
0.00109%
ProShares Ultra Russell2000
UWM
3.77731127157404e-4%
ProShares Hedge Replication ETF
HDG
1.9421563799476015e-4%
ProShares UltraPro Russell2000
URTY
1.7282742178948004e-4%
Global X Russell 2000 Covered Call ETF
RYLD
0%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Russell 2000 Value Index Fund
VTWV
0%
Vanguard Extended Market Index Fund
VXF
0%